Comparative Pharmacology
Head-to-head clinical analysis: BIAXIN versus PEDIAMYCIN.
Peer-Reviewed Evidence
Head-to-head clinical analysis: BIAXIN versus PEDIAMYCIN.
BIAXIN vs PEDIAMYCIN
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Binds to the 50S ribosomal subunit, inhibiting bacterial protein synthesis by blocking peptide chain elongation.
Erythromycin is a macrolide antibiotic that binds to the 50S subunit of the bacterial ribosome, inhibiting protein synthesis by blocking translocation of peptidyl-tRNA. It may be bacteriostatic or bactericidal depending on concentration and organism.
250-500 mg orally every 12 hours for 7-14 days; extended-release: 1000 mg orally every 24 hours for 7-14 days
250-500 mg orally every 6 hours; maximum 2 g/day.
None Documented
None Documented
Terminal elimination half-life: 3-7 hours (single dose, 250-500 mg); with multiple dosing, half-life may extend to 7-10 hours due to saturable metabolism. Clinical context: Shorter half-life requires twice-daily dosing; extended half-life (via 14-hydroxy metabolite, t1/2 ~11 h) contributes to antibacterial activity.
The terminal elimination half-life is approximately 1.5-2 hours in adults with normal renal function. In patients with severe hepatic impairment, half-life may be prolonged to 5-6 hours. The short half-life necessitates frequent dosing (every 6-8 hours) to maintain therapeutic levels.
Approximately 20-30% of administered dose is excreted unchanged in urine; remainder is hepatically metabolized and excreted in bile and feces (~50% fecal elimination).
PEDIAMYCIN (erythromycin ethylsuccinate) is primarily excreted via the biliary route (60-70% as unchanged drug and metabolites) with significant fecal elimination. Renal excretion accounts for only 5-15% of the dose, mostly as inactive metabolites. Less than 5% is excreted unchanged in urine.
Category C
Category C
Macrolide Antibiotic
Macrolide Antibiotic